Elan launches trials on Tysabri

ELAN and its partner Biogen Idec have begun a new trial on patients of the multiple sclerosis drug, Tysabri, banned from the market in February 2005.

That followed the deaths of two patients, who contacted a rare brain disease.

Company shares rose 18 cent to €12 on the news.